As 2018 approaches, the anti-epilepsy market is getting more attention in the pharma scene. The significant drivers of growth in this area are the development of third generation drugs, increased screening of patients, and improved access to anti-epilepsy treatments.
Significant market constraints include the high cost of clinical trials and the need for high-level post market surveillance.
What's in the pipeline for 2018? According to Pharma Exec's 2018 Pipeline Report:
"GW Pharmaceuticals leads the way with its cannabinoid product Epidiolex, which treats Dravet syndrome, Lennox-Gastaut syndrome, and other severe forms of epilepsy. Epidiolex is in Phase III for both indications, as well as tuberous sclerosis, and has received orphan designation from the European Medicines Agency (EMA). Evaluate estimates Epidiolex’s 2022 sales at $1 billion. Despite delays, the drug seems poised for FDA approval."